These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34224699)

  • 21. Gracilaria chorda subcritical water ameliorates hepatic lipid accumulation and regulates glucose homeostasis in a hepatic steatosis cell model and obese C57BL/6J mice.
    Thakuri LS; Park CM; Kim HA; Kim HJ; Park JW; Park JC; Rhyu DY
    J Ethnopharmacol; 2024 Feb; 320():117395. PubMed ID: 37952731
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Schisandrin B mitigates hepatic steatosis and promotes fatty acid oxidation by inducing autophagy through AMPK/mTOR signaling pathway.
    Yan LS; Zhang SF; Luo G; Cheng BC; Zhang C; Wang YW; Qiu XY; Zhou XH; Wang QG; Song XL; Pan SY; Zhang Y
    Metabolism; 2022 Jun; 131():155200. PubMed ID: 35405150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of NAMPT aggravates high fat diet-induced hepatic steatosis in mice through regulating Sirt1/AMPKα/SREBP1 signaling pathway.
    Wang LF; Wang XN; Huang CC; Hu L; Xiao YF; Guan XH; Qian YS; Deng KY; Xin HB
    Lipids Health Dis; 2017 Apr; 16(1):82. PubMed ID: 28449683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hesperidin attenuates hepatic lipid accumulation in mice fed high-fat diet and oleic acid induced HepG2 via AMPK activation.
    Chen H; Nie T; Zhang P; Ma J; Shan A
    Life Sci; 2022 May; 296():120428. PubMed ID: 35218767
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Theobromine ameliorates nonalcoholic fatty liver disease by regulating hepatic lipid metabolism via mTOR signaling pathway in vivo and in vitro.
    Wei D; Wu S; Liu J; Zhang X; Guan X; Gao L; Xu Z
    Can J Physiol Pharmacol; 2021 Aug; 99(8):775-785. PubMed ID: 33290156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK-mTOR Interplay.
    Chen H; Tran D; Yang HC; Nylander S; Birnbaum Y; Ye Y
    Cardiovasc Drugs Ther; 2020 Aug; 34(4):443-461. PubMed ID: 32335797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chicoric Acid Ameliorates Nonalcoholic Fatty Liver Disease via the AMPK/Nrf2/NF
    Ding X; Jian T; Li J; Lv H; Tong B; Li J; Meng X; Ren B; Chen J
    Oxid Med Cell Longev; 2020; 2020():9734560. PubMed ID: 33204402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Delayed intervention with a novel SGLT2 inhibitor NGI001 suppresses diet-induced metabolic dysfunction and non-alcoholic fatty liver disease in mice.
    Chiang H; Lee JC; Huang HC; Huang H; Liu HK; Huang C
    Br J Pharmacol; 2020 Jan; 177(2):239-253. PubMed ID: 31497874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Salidroside and Curcumin Formula Prevents Liver Injury in Nonalcoholic Fatty Liver Disease in Rats.
    Li HS
    Ann Hepatol; 2018 Aug; 17(5):769-778. PubMed ID: 30145577
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Bae S; Lee YH; Lee J; Park J; Jun W
    Nutrients; 2022 Dec; 14(24):. PubMed ID: 36558538
    [No Abstract]   [Full Text] [Related]  

  • 31. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Shimizu M; Suzuki K; Kato K; Jojima T; Iijima T; Murohisa T; Iijima M; Takekawa H; Usui I; Hiraishi H; Aso Y
    Diabetes Obes Metab; 2019 Feb; 21(2):285-292. PubMed ID: 30178600
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thymoquinone attenuates hepatic lipid accumulation by inducing autophagy via AMPK/mTOR/ULK1-dependent pathway in nonalcoholic fatty liver disease.
    Zhang D; Zhang Y; Wang Z; Lei L
    Phytother Res; 2023 Mar; 37(3):781-797. PubMed ID: 36479746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dapagliflozin Attenuates Na
    Ye Y; Jia X; Bajaj M; Birnbaum Y
    Cardiovasc Drugs Ther; 2018 Dec; 32(6):553-558. PubMed ID: 30367338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Honokiol activates the LKB1-AMPK signaling pathway and attenuates the lipid accumulation in hepatocytes.
    Seo MS; Kim JH; Kim HJ; Chang KC; Park SW
    Toxicol Appl Pharmacol; 2015 Apr; 284(2):113-24. PubMed ID: 25737164
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gastrodin Improves Nonalcoholic Fatty Liver Disease Through Activation of the Adenosine Monophosphate-Activated Protein Kinase Signaling Pathway.
    Wan J; Zhang Y; Yang D; Liang Y; Yang L; Hu S; Liu Z; Fang Q; Tian S; Ding Y
    Hepatology; 2021 Dec; 74(6):3074-3090. PubMed ID: 34297426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Procyanidin B2 ameliorates free fatty acids-induced hepatic steatosis through regulating TFEB-mediated lysosomal pathway and redox state.
    Su H; Li Y; Hu D; Xie L; Ke H; Zheng X; Chen W
    Free Radic Biol Med; 2018 Oct; 126():269-286. PubMed ID: 30142454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liensinine alleviates high fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD) through suppressing oxidative stress and inflammation via regulating TAK1/AMPK signaling.
    Liang L; Ye S; Jiang R; Zhou X; Zhou J; Meng S
    Int Immunopharmacol; 2022 Mar; 104():108306. PubMed ID: 34999396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tetrahydropalmatine ameliorates hepatic steatosis in nonalcoholic fatty liver disease by switching lipid metabolism via AMPK-SREBP-1c-Sirt1 signaling axis.
    Yin X; Liu Z; Wang J
    Phytomedicine; 2023 Oct; 119():155005. PubMed ID: 37562090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Asperuloside alleviates lipid accumulation and inflammation in HFD-induced NAFLD via AMPK signaling pathway and NLRP3 inflammasome.
    Shen Q; Chen Y; Shi J; Pei C; Chen S; Huang S; Li W; Shi X; Liang J; Hou S
    Eur J Pharmacol; 2023 Mar; 942():175504. PubMed ID: 36641101
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice.
    Ideta T; Shirakami Y; Miyazaki T; Kochi T; Sakai H; Moriwaki H; Shimizu M
    Int J Mol Sci; 2015 Dec; 16(12):29207-18. PubMed ID: 26670228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.